Navigation Links
ULURU Inc. Announces the Expansion of the International Marketing Network
Date:12/11/2013

ADDISON, Texas, Dec. 11, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR), today announced the expansion of the Altrazeal® international marketing network. Agreements have been signed granting the exclusive marketing and distribution rights for Altrazeal® in Italy, Spain and Greece.

Commenting on the extension of the international marketing network, Helmut Kerschbaumer, Managing Director of Altrazeal GmbH, stated, "These agreements are an important step in the commercialization of Altrazeal®, as Italy and Spain are major markets in the European Union. Positive clinical experiences have already been generated and we are now working to expeditiously launch Altrazeal® into these markets. We continue to execute on our objective to appoint highly qualified marketing partners in all countries throughout our licensed territory."

Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing. Altrazeal® competes in the advanced wound dressing market which, worldwide, is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers and geriatric wounds.

Kerry P. Gray, President and CEO of ULURU Inc., stated, "Great progress has been made to establish a global marketing network for Altrazeal®. As Altrazeal represents a cost effective approach for the treatment of acute and chronic wounds there is an opportunity to establish a truly global marketing network. We are working closely with Altrazeal GmbH to have Altrazeal® available for marketing in these countries as quickly as possible."

About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.ULURUinc.com.  For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to the launch of Altrazeal® in the territory, the commercial potential of Altrazeal® and the demonstration of cost savings and clinical benefits, and the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Reports Third Quarter 2013 Financial Results
2. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Third Quarter Ended September 30, 2013
3. ULURU Inc. Completes Redemption Of Preferred Stock
4. ULURU Inc. Reports Second Quarter 2013 Financial Results
5. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
6. ULURU Inc. Reports First Quarter 2013 Financial Results
7. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
8. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
9. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
10. ULURU Inc. Business Update And Outlook
11. ULURU Inc. Announces Closing Of $440,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
(Date:9/9/2017)... 8, 2017 Dealmed Medical Supplies, ... medical equipment, supplies, drugs, vaccines, and specialty medical products ... an agreement to acquire Vantage Medical Supplies, a major ... Holtsville, New York . ... and emerging medical practices, will operate under the Dealmed ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 19, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) , ... in healthcare information exchange and a trusted advisor to the U.S. Department of Health ... entitled Barriers to Adoption of the ERA and EFT Transactions . , ...
(Date:9/19/2017)... , ... September 19, 2017 , ... Public outrage over ... pollutants have fallen on deaf ears, leaving the water industry itself to research, develop ... stays ahead of the curve in the field of natural alkaline water ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void ... first in the U.S. to incorporate magnesium, a critical property for bone health ...
(Date:9/19/2017)... , ... September 19, 2017 , ... Ron Norman, CEO ... today the importance of making a distinct rather than generic impression in the job ... to look through a stack of resumes knows that the first impression they give ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... positively linked to the Certified Emergency Nurse (CEN®) certification according to ... (BCEN). The value of certification study, conducted by the Human Resources Research Organization ...
Breaking Medicine News(10 mins):